Nebulized Ipratropium Bromide-induced Anisocoria: Why Is Anisocoria Observed?

DERİNÖZ GÜLERYÜZ O., Fidanci İ., MEN ATMACA Y.

Iranian journal of allergy, asthma, and immunology, cilt.20, sa.1, ss.125-128, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 20 Sayı: 1
  • Basım Tarihi: 2021
  • Doi Numarası: 10.18502/ijaai.v20i1.5420
  • Dergi Adı: Iranian journal of allergy, asthma, and immunology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals
  • Sayfa Sayıları: ss.125-128
  • Gazi Üniversitesi Adresli: Evet

Özet

Pharmacological anisocoria is a rare but benign condition. This paper presents an eleven-year-old patient with asthma who developed ipratropium bromide-associated anisocoria during nebulizer treatment. Hypotheses regarding the possible causes of anisocoria are discussed and precautions to be taken during treatment are presented. To prevent the development of anisocoria, it was found that it is important to use the appropriate mask during nebulizer treatment, to place the mask on the face properly, and, if possible, to administer drugs by closing the eyes. Further, it is recommended that patients undergo an ophthalmological examination before discharge and that they and their families be informed that the condition is temporary.